UGENTi002-A-1
General
iPSC Line |
|
| hPSCreg name | UGENTi002-A-1 |
| Cite as: | UGENTi002-A-1 (RRID:CVCL_D0MN) |
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines |
FAMRCi011-B (ARVC51b) Donor's gene variants: FLNC Donor diseases: Inherited arrhythmogenic cardiomyopathy JHUi010-A (JHU013, Clone 2) Donor's gene variants: desmoglein 2 Donor diseases: Inherited arrhythmogenic cardiomyopathy |
| Last update | 3rd July 2024 |
| User feedback | |
Provider |
|
| Generator |
Ghent University (UGENT)
Contact:
Ghent University (UGENT) |
| Owner | Ghent University (UGENT) |
| Distributors | |
| Derivation country | Belgium |
External iPSC Databases |
|
| BioSamples | SAMEA113958745 |
| Cellosaurus | CVCL_D0MN |
| Wikidata | Q123033697 |
General iPSC Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
iPSC Genetic Modification
| Disease/phenotype related modifications |
|
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA113939457 |
Ethics
Also have a look at the ethics information for the parental line
UGENTi002-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
UGENTi002-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Flat morphology with rounded edges, desirable growth, expression of pluripotency markers |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzymatically
TrypLE
|
||||||
| O2 Concentration | 5 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
Essential 8™
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
morphology.tif
scalebar = 400µm
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
Genotyping
Karyotyping (iPSC Line) |
|
Other Genotyping (iPSC Line) |
Login to share your feedback, experiences or results with the research community.